<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060263</url>
  </required_header>
  <id_info>
    <org_study_id>HOT-1030-1</org_study_id>
    <nct_id>NCT05060263</nct_id>
  </id_info>
  <brief_title>A Study of of HOT1030 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT1030 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huabo Biopharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huabo Biopharm Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT-1030&#xD;
      in Patients with Advanced Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, Phase 1, study to evaluate the safety, tolerability, PK, and PD&#xD;
      profiles of HOT-1030 as a monotherapy to assess the maximum tolerated dose (MTD) in subjects&#xD;
      with advanced solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>dose-escalation study</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by incidence of AEs (Adverse Events)</measure>
    <time_frame>through study completion， an average of 1 year</time_frame>
    <description>Incidence and severity of AEs, Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of HOT-1030</measure>
    <time_frame>42 days</time_frame>
    <description>Area under the concentration-time curve of HOT-1030 in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of HOT-1030</measure>
    <time_frame>42 days</time_frame>
    <description>Maximum Serum Concentration (Cmax) in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of HOT-1030 in Patients With advanced Solid Tumors</measure>
    <time_frame>through study completion， an average of 1 year</time_frame>
    <description>Response is defined as a Complete Response + Partial Response and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HOT-1030, every 21 days by intravenous administration. HOT-1030 is a recombinant humanized CD137 monoclonal antibody injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HOT-1030</intervention_name>
    <description>HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <other_name>no other interventions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female from 18 to 75 yrs (include 18 yrs and 75 yrs).&#xD;
&#xD;
          2. Willing and able to provide signed and dated informed consent prior to any&#xD;
             study-related procedures and willing and able to comply with all study procedures.&#xD;
&#xD;
          3. Patients with histologically or cytologically confirmed advanced malignant solid tumor&#xD;
             who have received or been intolerant of all standard therapies thought to confer&#xD;
             clinical benefit.&#xD;
&#xD;
          4. Measurable disease on imaging base on RECIST v1.1 for solid tumors;&#xD;
&#xD;
          5. Stop anticancer therapy for more than 5 half-lives or 4 weeks (whichever is shorter)&#xD;
             prior to study entry;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          7. Adequate organ function, as indicated by the laboratory values.&#xD;
&#xD;
          8. Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening; Male patients and the female patients of childbearing potential must agree&#xD;
             to use highly effective contraceptive measures throughout the study starting with the&#xD;
             Screening Visit through 90 days after the last dose of study treatment is received.&#xD;
&#xD;
          9. Life expectancy &gt;3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any anti-CD137 antibodies.&#xD;
&#xD;
          2. Active primary CNS tumor or metastatic CNS tumor (expect the patients who had received&#xD;
             the treatment and stopped the treatment for more than 4 weeks before first dose),&#xD;
             active epilepsy, Spinal cord compression or Cancerous meningitis.&#xD;
&#xD;
          3. Active autoimmune disease or history of autoimmune disease requiring systemic therapy&#xD;
             &lt; 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease,&#xD;
             Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that&#xD;
             has not been active in the 2 years prior to study screening are eligible.&#xD;
&#xD;
          4. Require systematic anti-infective therapy a week before first dose because of active&#xD;
             infection.&#xD;
&#xD;
          5. Taken the surgical operations not related to the research 4 weeks before first dose&#xD;
&#xD;
          6. Used of systemic corticosteroids (a dose equivalent &gt; 10 mg/day of prednisone or )or&#xD;
             other immunosuppressive agents, excepted:&#xD;
&#xD;
               1. Patients are allowed to have topical use or inhaled glucocorticoid.&#xD;
&#xD;
               2. Patients are allowed to have a less than seven-day glucocorticoid treatment&#xD;
                  preventing or treat non-autoimmune allergic diseases.&#xD;
&#xD;
          7. The toxicity of previous anti-tumor therapy has not recovered (defined as not&#xD;
             recovering to grade 0 or 1, except for alopecia) or has not fully recovered from&#xD;
             previous surgery.&#xD;
&#xD;
          8. During the 6 months prior to screening, the patient had a history of major&#xD;
             cardiovascular and cerebrovascular events, such as myocardial infarction, coronary&#xD;
             angioplasty or bypass surgery, heart valve repair, unstable arrhythmias, unstable&#xD;
             angina, transient ischemic attack, or cerebrovascular accidents.&#xD;
&#xD;
          9. New York Heart Association (NYHA) grade III or IV congestive heart failure.&#xD;
&#xD;
         10. Patients with uncontrolled hypertension (systolic blood pressure ≥160mmHg or diastolic&#xD;
             blood pressure ≥100mmHg at the time of screening) who had been on a stable dose of&#xD;
             antihypertensive drugs for at least 4 weeks at the time of screening).&#xD;
&#xD;
         11. Active hepatitis B (hepatitis B virus titer &gt;103 copies /ml or 200IU/ml); Hepatitis C&#xD;
             virus infection (HCV-RNA above the detection limit); Prophylaxis antiviral therapy&#xD;
             other than interferon is allowed. In patients with advanced liver cancer (HCC),&#xD;
             hepatitis B virus titer &gt;104 copies /ml or 2000IU/ml should be excluded.&#xD;
&#xD;
         12. A history of known congenital and acquired immunodeficiency, including positive HIV&#xD;
             antibody tests.&#xD;
&#xD;
         13. Patients with a known history of severe allergic reactions to macromolecular protein&#xD;
             formulations/monoclonal antibodies or to any investigational drug component (CTCAE&#xD;
             V5.0 grade greater than 3).&#xD;
&#xD;
         14. Participated in clinical trials of other drugs within 4 weeks before the first&#xD;
             administration.&#xD;
&#xD;
         15. Pregnant or lactating women or women at risk of pregnancy have a positive pregnancy&#xD;
             test before the first medication.&#xD;
&#xD;
         16. Other investigators consider that the patient has any clinical or laboratory&#xD;
             abnormality that makes him unsuitable for participation in this clinical study.&#xD;
&#xD;
         17. prior history of a clear neurological or psychiatric disorder, including epilepsy or&#xD;
             dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Baohui, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yang yongming, Doctor</last_name>
    <phone>18964167352</phone>
    <phone_ext>+86</phone_ext>
    <email>yongmin.yang@huaota.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Huaota Biopharmaceutical Co., Ltd.</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang yongming, doctor</last_name>
      <phone>18964167352</phone>
      <email>杨永民&lt;yongmin.yang@huaota.com&gt;</email>
    </contact>
    <investigator>
      <last_name>Han Baohui, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

